Molecular targets for the treatment of fibrosing cholangiopathies

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 3, 2012, Pages 381-387

  Maillette De Buy Wenniger, L J ^a   Oude Elferink, R P ^a   Beuers, U ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICHOLELITHIASIS AGENT; BEZAFIBRATE; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CALCIUM; CELL NUCLEUS RECEPTOR; CHENODEOXYCHOLIC ACID; COLESTYRAMINE; FENOFIBRATE; GLUCOCORTICOID; NALTREXONE; NORURSODEOXYCHOLIC ACID; OBETICHOLIC ACID; PLACEBO; PREDNISOLONE; RIFAMPICIN; RITUXIMAB; SERTRALINE; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; VITAMIN D;

ALBUMIN DIALYSIS; ARTICLE; AUTOIMMUNE HEPATITIS; BILE DUCT DISEASE; BILE DUCT OBSTRUCTION; BILIARY TRACT DRAINAGE; CELL PROTECTION; CELL TYPE; CHOLANGIOCYTE; CHOLANGITIS; CHOLESTASIS; CHOLESTATIC PRURITUS; DISEASE COURSE; DRUG MECHANISM; DRUG MEGADOSE; DYSLIPIDEMIA; FIBROSING CHOLANGIOPATHY; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE SYSTEM; INTRAHEPATIC CHOLESTASIS; LIVER CELL; LIVER TOXICITY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PLASMAPHERESIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCLEROSING CHOLANGITIS; ULTRAVIOLET RADIATION;

BILIARY TRACT; CHOLANGITIS, SCLEROSING; CHOLESTASIS; HEPATOCYTES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; URSODEOXYCHOLIC ACID;

EID: 84865434522     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.111     Document Type: Article

References (40)

1. Paumgartner, G. & Pusl, T. Medical treatment of cholestatic liver disease. Clin. Liver Dis. 12, 53-80, viii (2008). (Pubitemid 351163144)
2. Hohenester, S., Oude-Elferink, R.P. & Beuers, U. Primary biliary cirrhosis. Semin. Immunopathol. 31, 283-307 (2009).
3. Chapman, R. et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 51, 660-678 (2010).
4. Boberg, K.M., Chapman, R.W., Hirschfeld, G.M., Lohse, A.W., Manns, M.P. & Schrumpf, E. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J. Hepatol. 54, 374-385 (2011).
5. Ruemmele, P., Hofstaedter, F. & Gelbmann, C.M. Secondary sclerosing cholangitis. Nat. Rev. Gastroenterol. Hepatol. 6, 287-295 (2009).
6. Ghazale, A. et al. Immunoglobulin G4-associated cholangitis: clinical profle and response to therapy. Gastroenterology 134, 706-715 (2008). (Pubitemid 351312724)
7. Maillette de Buy Wenniger, L. & Beuers, U. Bile salts and cholestasis. Dig. Liver Dis. 42, 409-418 (2010).
8. Stieger, B., Meier, Y. & Meier, P.J. The bile salt export pump. Pfugers Arch. 453, 611-620 (2007). (Pubitemid 46192534)
9. Wagner, M., Zollner, G. & Trauner, M. Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis. Semin. Liver Dis. 30, 160-177 (2010).
10. Stieger, B. & Beuers, U. The canalicular bile salt export pump BSEP (ABCB11) as a potential therapeutic target. Curr. Drug Targets 12, 661-670 (2011).
11. Dombrowski, F., Stieger, B. & Beuers, U. Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver. Lab. Invest. 86, 166-174 (2006). (Pubitemid 43117596)
12. Beuers, U., Hohenester, S., de Buy Wenniger, L.J., Kremer, A.E., Jansen, P.L. & Elferink, R.P. The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fbrosing cholangiopathies. Hepatology 52, 1489-1496 (2010).
13. - umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology 55, 173-183 (2012).
14. Beuers, U. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat. Clin. Pract. Gastroenterol. Hepatol. 3, 318-328 (2006). (Pubitemid 43842248)
15. Keitel, V., Ullmer, C. & Häussinger, D. The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes. Biol. Chem. 391, 785-789 (2010).
16. Minagawa, N. et al. Cyclic AMP regulates bicarbonate secretion in cholangiocytes through release of ATP into bile. Gastroenterology 133, 1592-1602 (2007). (Pubitemid 350029742)
17. Hov, J.R., Keitel, V., Schrumpf, E., Häussinger, D. & Karlsen, T.H. TGR5 sequence variation in primary sclerosing cholangitis. Dig. Dis. 29, 78-84 (2011).
18. Pellicciari, R. et al. Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J. Med. Chem. 52, 7958-7961 (2009).
19. 3 output. Hepatology 54, 1303-1312 (2011).
20. Fiorotto, R., Spirlì, C., Fabris, L., Cadamuro, M., Okolicsanyi, L. & Strazzabosco, M. Ursodeoxycholic acid stimulates cholangiocyte fuid secretion in mice via CFTR-dependent ATP secretion. Gastroenterology 133, 1603-1613 (2007). (Pubitemid 350029752)
21. Woo, K., Dutta, A.K., Patel, V., Kresge, C. & Feranchak, A.P. Fluid fow induces mechanosensitive ATP release, calcium signalling and Cl-transport in biliary epithelial cells through a PKCzeta-dependent pathway. J. Physiol. (Lond.) 586, 2779-2798 (2008). (Pubitemid 351761791)
22. Dutta, A.K., Woo, K., Doctor, R.B., Fitz, J.G. & Feranchak, A.P. Extracellular nucleotides stimulate Cl-currents in biliary epithelia through receptor-mediated IP3 and Ca2+ release. Am. J. Physiol. Gastrointest. Liver Physiol. 295, G1004-G1015 (2008).
23. Masyuk, A.I. et al. Cholangiocyte primary cilia are chemosensory organelles that detect biliary nucleotides via P2Y12 purinergic receptors. Am. J. Physiol. Gastrointest. Liver Physiol. 295, G725-G734 (2008).
24. Nathanson, M.H., Burgstahler, A.D., Masyuk, A. & Larusso, N.F. Stimulation of ATP secretion in the liver by therapeutic bile acids. Biochem. J. 358, 1-5 (2001). (Pubitemid 32778091)
25. Mizumori, M., Ham, M., Guth, P.H., Engel, E., Kaunitz, J.D. & Akiba, Y. Intestinal alkaline phosphatase regulates protective surface microclimate pH in rat duodenum. J. Physiol. (Lond.) 587, 3651-3663 (2009).
26. Alvaro, D. et al. The function of alkaline phosphatase in the liver: regulation of intrahepatic biliary epithelium secretory activities in the rat. Hepatology 32, 174-184 (2000). (Pubitemid 30614648)
27. Beuers, U., Nathanson, M.H., Isales, C.M. & Boyer, J.L. Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis. J. Clin. Invest. 92, 2984-2993 (1993). (Pubitemid 24006569)
28. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 51, 237-267 (2009).
29. Corpechot, C. et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 48, 871-877 (2008).
30. Olsson, R. et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 129, 1464-1472 (2005). (Pubitemid 41597389)
31. Kondrackiene, J., Beuers, U. & Kupcinskas, L. Efcacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 129, 894-901 (2005). (Pubitemid 41242682)
32. Leuschner, M. et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 117, 918-925 (1999). (Pubitemid 29468235)
33. Hempfing, W., Grunhage, F., Dilger, K., Reichel, C., Beuers, U. & Sauerbruch, T. Pharmacokinetics and pharmacodynamic action of budesonide in early-and late-stage primary biliary cirrhosis. Hepatology 38, 196-202 (2003). (Pubitemid 36775811)
34. Iwasaki, S. et al. The efcacy of ursodeoxycholic acid and bezafbrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study. Hepatol. Res. 38, 557-564 (2008). (Pubitemid 351622281)
35. Kremer, A.E., Oude Elferink, R.P. & Beuers, U. Pathophysiology and current management of pruritus in liver disease. Clin. Res. Hepatol. Gastroenterol. 35, 89-97 (2011).
36. Fickert, P. et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 130, 465-481 (2006). (Pubitemid 43202044)
37. Halilbasic, E. et al. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/-mice. Hepatology 49, 1972-1981 (2009).
38. Denk, G.U. et al. Conjugation is essential for the anticholestatic efect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver. Hepatology 52, 1758-1768 (2010).
39. Hofmann, A.F. Bile acids: trying to understand their chemistry and biology with the hope of helping patients. Hepatology 49, 1403-1418 (2009).
40. Pellicciari, R. et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 45, 3569-3572 (2002). (Pubitemid 34856095)